Kaitlyn Bader, Senior Editor

Care Messenger helps to expand care delivery and respond to growing patient needs without placing additional strain on clinicians.

In case you missed it, this week we had news about roflumilast foam's efficacy in diverse hair types of seborrheic dermatitis, Lindus Health's new partnership to evaluate a benzoyl peroxide alternative, sonelokimab advancing to phase 3 for HS, and more.

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

VELA is the first phase 3 hidradenitis suppurativa trial to evaluate HiSCR75 as the primary end point.

Acinonyx Bio's topical cream, ACX, targets Propionibacterium acnes.

The needs assessment surveyed patients’ stage of treatment, radiation-induced dermatologic adverse effects, and over-the-counter products and home remedies that were used.

Muscle spasms are the most common adverse event experienced by patients treated with hedgehog inhibitors for basal cell carcinomas.

This week’s collection of the latest dermatologic studies includes artificial intelligence in cutaneous lesions, dupilumab-induced acanthosis nigricans, aesthetic considerations for treating lesbian, gay, and bisexual patients, and monotherapies for male androgenetic alopecia.

In case you missed it, this week we had news about skin cancer resources to share with patients, positive phase 3 results of imsidolimab for GPP, improvement in anxiety and depression after 2 years of treatment with dupilumab for AD, and more.

Patients who responded to imsidolimab in GEMINI-1 and who moved into GEMINI-2 maintained clear or almost clear skin.

VYNE expects to enroll the first patient with vitiligo in the phase 2b trial for VYN201 in the second quarter of 2024.

Renata Block, MMS, PA-C, shares her favorite topics from the aesthetic conference held last month.

The awarded grant will span a total of 3 years.

Marc Hurlbert, PhD, discusses how the Melanoma Research Alliance works with dermatology clinicians to provide fundings and resources for melanoma research.

The Harris brothers serve 2 predominantly elderly populations and appreciate the opportunity to provide solutions for the growing complexity of skin cancer issues as patients live longer.

In case you missed it, this week we had news about Dermavant's FDA-accepted sNDA for tapinarof cream 1% for AD, Eli Lilly's resubmitted BLA for lebrikizumab for AD, Rosacea Awareness Month recaps, and more.

This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.

The new research will compare eblasakimab to dupilumab and lebrikizumab.

Review Dermatology Times' coverage of Rosacea Awareness Month.

A decision from the FDA is expected in the second half of 2024.

López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.

The FDA’s PDUFA date is expected in quarter 4 of 2024.

Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.

Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.

Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.

Hasbargen presented Mohs surgery pearls on closure types and pattern recognition at the 2024 Diversity in Dermatology meeting.

ICYMI, this week we had news about partnering with Spherix Global Insights, a look back at the rosacea pipeline, what dermatology clinicians need to know about recent counterfeit Botox, and more.

Blackburn presented integrative medicine pearls on gut and hormone health at the 2024 Diversity in Dermatology meeting.

Scurto presented integrative medicine pearls at the 2024 Diversity in Dermatology meeting.